News & Publications
Find our latest news and analysis here. From the daily Newsstand to the Quarterly Journal, we cover the full breadth of intellectual property law.
Written April 4, 2019
The US Court of Appeals for the Federal Circuit on April 1, 2019, held the Cleveland Clinic Foundation’s heart disease detection patent invalid because the claims of the patent were directed to a natural law and recited no other inventive concept. Cleveland Clinic Found. v. True Health Diagnostics LLC, Fed. Cir., No. 2018-1218, 4/1/19.
The patents disclose several methods of measuring a patient’s blood MPO level. The Court concluded that the claims were directed to the natural law that blood MPO levels correlate a patient’s level of myeloperoxidase (MPO), a naturally occurring protein that exists in higher levels in the blood of heart disease patients.
The patents disclose several methods of measuring a patient’s blood MPO level. The Court concluded that the claims were directed to the natural law that blood MPO levels correlate a patient’s level of myeloperoxidase (MPO), a naturally occurring protein that exists in higher levels in the blood of heart disease patients.
Broadcast Opportunities
Looking for opportunities to get published? Submit your work to the AIPLA Quarterly Journal or AIPLA Innovate Magazine.
Exhibitor and Sponsorship Opportunities
Highlight your brand at a premier intellectual property law event, webinar, podcast, or in one of our publications.
For rates, availability, or additional details, click here or contact:
Meghan Donohoe
COO
American Intellectual Property Law Association (AIPLA)
T| +1.703.415.1343
E| mdonohoe@aipla.org